Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. PIASCLEDINE (insaponifiable d’huile d’avocat/ insaponifiable d’huile de soja)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

PIASCLEDINE (insaponifiable d’huile d’avocat/ insaponifiable d’huile de soja)

Medicine - Posted on Jul 25 2013 - Updated on Jun 12 2019
Active substance (DCI)
  • insaponifiable d’huile d’avocat
  • insaponifiable d’huile de soja
history (4)
  • 1/9/13

    PIASCLEDINE

    -
    icône flèche
  • 9/21/11

    PIASCLEDINE (insaponifiable d’huile d’avocat/ insaponifiable d’huile de soja)

    PIASCLEDINE (insaponifiable d’huile d’avocat/ insaponifiable d’huile de soja)
    icône flèche
  • 11/26/08

    PIASCLEDINE

    PIASCLEDINE
    icône flèche
  • 2/15/06

    PIASCLEDINE 300 mg, géluleBoite de 15 gélules (321 495- 4)

    PIASCLEDINE 300 mg, géluleBoite de 15 gélules (321 495- 4)
    icône flèche
Technical information
ATC code
  • M01AX26
Manufacturer
EXPANSCIENCE
Presentation

PIASCLEDINE 300 mg, gélule
Boîte de 15 gélules- Code CIP : 34009 321 495 4 4

All our publications
    Dental and mouth diseases - miscellaneous Drug therapy Joint and rheumatic diseases Pain - Inflammation

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
HFM66nsfPVuMLkdr